Is TB-500 Legal in Louisiana? How to Access It Legally

What TB-500 Actually Is

TB-500 is a synthetic peptide derived from the conserved actin-binding region of thymosin beta-4 (TB4), a 43-amino-acid protein encoded by the TMSB4X gene. The active fragment, Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), accounts for much of TB4's studied effects on cell migration, inflammation modulation, and angiogenesis.

Thymosin Beta-4 vs. TB-500

The two terms are often used interchangeably online, but they are not identical. Thymosin beta-4 is the full endogenous protein. TB-500 is a shorter synthetic peptide reproducing only the Ac-SDKP motif. Researchers have investigated full-length TB4 in cardiac injury models. RegeneRx Biopharmaceuticals ran Phase II trials of full-length thymosin beta-4 (RGN-352) in acute myocardial infarction and corneal repair, not TB-500 specifically. The distinction matters legally because the FDA's regulatory actions name specific substances.

Why Athletes and Patients Are Interested

Preclinical data in rodent and equine models suggest TB-500 may accelerate wound healing, reduce inflammation, and support connective-tissue repair. A 2010 study in the Journal of Molecular Medicine showed thymosin beta-4 reduced myocardial infarct size by roughly 50% in a mouse model (PMID 20179937). Human clinical evidence remains limited. WADA added thymosin beta-4 to its Prohibited List (S2 category) in 2012, which tells you how seriously performance-sport authorities take its potential biological activity, even absent large randomized controlled trials in humans.

The Federal Legal Framework for TB-500

The federal picture is complicated, and being clear about that complexity is the only responsible approach.

FDA Approval Status

TB-500 holds no FDA approval for any human indication. The FDA has not issued a New Drug Application (NDA) or Biologics License Application (BLA) for TB-500. Without approval, no manufacturer can legally market it as a drug for human use in the United States. That baseline fact applies in every state, including Louisiana.

The 503A and 503B Compounding Pathways

Compounding pharmacies can legally prepare certain non-approved substances under two federal frameworks established by the Drug Quality and Security Act of 2013:

• 503A pharmacies compound for individual patients with a valid prescription. They may use bulk drug substances that appear on the FDA's "positive list" (21 CFR 216.24) or that are under active clinical evaluation.
• 503B outsourcing facilities compound larger batches without patient-specific prescriptions. They may only use bulk substances explicitly placed on their own positive list.

The FDA evaluates bulk substances through a nomination process. TB-500 (listed under "thymosin beta-4" and related analogues) was nominated and has been placed in Category 2, which means the FDA found "insufficient clinical evidence of safety and effectiveness" based on currently available data to add it to the positive list. The FDA's full bulk-drug substance list and category assignments are published and updated at FDA.gov.

A Category 2 designation does not make TB-500 a controlled substance, and it does not criminalize possession. What it does mean, practically, is that 503A pharmacies operating within the rules should not be compounding TB-500 for human use until the FDA resolves its rulemaking. 503B outsourcing facilities face the same restriction.

Is It a Controlled Substance?

No. TB-500 does not appear on Schedules I through V of the Controlled Substances Act (21 U.S.C. § 812). It is not an anabolic steroid, a stimulant, or a substance with recognized abuse potential under current DEA scheduling criteria. Possession of TB-500 for personal use is not a federal criminal offense in the way that possessing a Schedule I substance would be.

Louisiana's Legal Framework

Louisiana does not have a state statute that specifically names or bans TB-500. That absence does not mean the substance is freely legal for any use. State law layers on top of federal law, not underneath it.

Louisiana Pharmacy Practice Act

The Louisiana Board of Pharmacy regulates compounding under Louisiana Revised Statutes Title 37, §§ 1161 to 1177, and in its accompanying administrative code at Louisiana Administrative Code Title 46, Part LIII. Louisiana generally tracks federal USP standards and FDA guidance for non-sterile and sterile compounding. A Louisiana-licensed 503A pharmacy compounding TB-500 for human use would be operating inconsistently with FDA's Category 2 determination, putting its license at risk regardless of what state code says explicitly.

The Louisiana Board of Pharmacy's compounding guidance directs pharmacies to follow FDA bulk-substance lists. You can review current board policies at the Louisiana Board of Pharmacy directly, as policy documents update more frequently than statutory text.

Louisiana Medical Practice Act

Physicians licensed in Louisiana under Louisiana Revised Statutes Title 37, § 1261 et seq. Have broad authority to prescribe substances for their patients as long as those prescriptions are issued for a legitimate medical purpose and within the standard of care. Louisiana has not issued any Medical Board advisory that specifically restricts physician prescribing of TB-500. However, prescribing a substance that cannot be lawfully compounded creates a practical dead end: a valid prescription is necessary but not sufficient if no compliant pharmacy can fill it.

Louisiana Controlled Dangerous Substances Law

Louisiana's Uniform Controlled Dangerous Substances Law (Louisiana Revised Statutes Title 40, § 961 et seq.) mirrors the federal scheduling framework closely. TB-500 is not scheduled under Louisiana law. Possession, therefore, does not trigger state criminal penalties that apply to scheduled substances.

The Gray-Area Reality in Louisiana

Here is the honest summary of where Louisiana residents stand:

1. TB-500 is not a controlled substance at the federal or state level.
2. It is not FDA-approved.
3. It is on the FDA's Category 2 bulk list, blocking lawful compounding for human use under 503A/503B until rulemaking changes that status.
4. No Louisiana statute adds an independent layer of prohibition or an independent pathway to legal access.
5. Selling TB-500 online labeled "for research use only" sidesteps none of the above. That label does not confer legal protection on a vendor shipping a substance intended for human injection.

How People Currently Attempt to Access TB-500 in Louisiana

Understanding what pathways exist, and which are legally sound, helps patients make informed decisions.

Telehealth Peptide Clinics

A number of telehealth platforms prescribe peptide protocols to patients in Louisiana. A physician in one of these practices can write a prescription for TB-500. The prescription itself is legal. The problem arrives at the pharmacy: if the compounding pharmacy filling that prescription is not operating under an explicit FDA authorization or is treating TB-500 as though it were on the positive list when it is not, the pharmacy is the entity taking the regulatory risk. Patients should ask any prescribing clinic to name the specific compounding pharmacy, confirm that pharmacy's 503A or 503B registration, and request documentation that the pharmacy's quality assurance procedures cover the specific peptide being dispensed.

"Research Chemical" Vendors

Dozens of online vendors sell TB-500 labeled "for research purposes only, not for human use." This label is a legal fiction widely understood as such. The FDA has issued warning letters to vendors selling peptides under similar research-only designations for obvious human use. One example: the FDA issued warning letters in 2022 and 2023 to multiple companies selling BPC-157 and other peptides for injection under research-only labels, citing violations of the Federal Food, Drug, and Cosmetic Act. Purchasing TB-500 from these vendors for self-injection carries risks including unknown purity, incorrect dosing, contamination with endotoxins, and no medical oversight.

Veterinary Compounding

Thymosin beta-4 has been used in equine veterinary medicine. Some compounding pharmacies hold licenses for veterinary compounding. Using veterinary-compounded peptides in humans is not a recognized legal or clinical pathway. Products compounded for veterinary use are not manufactured to human sterile-injectable standards and are outside any legitimate prescribing framework for human patients.

The Science Behind TB-500: What Evidence Exists

The legal uncertainty around TB-500 tracks its clinical evidence base closely. Regulators generally move products to positive lists when strong human clinical data exists. That data remains thin.

Preclinical Findings

Animal studies have produced signals worth noting. A study published in Circulation (2010, PMID 20194878) showed systemic delivery of thymosin beta-4 activated cardiac progenitor cells after myocardial infarction in mice (full text via PubMed). A separate line of research in rodent tendon injury models (published in the Journal of Orthopaedic Research, 2013) found that locally applied TB4 improved collagen fiber alignment at six weeks post-injury. These are preclinical findings. They do not translate automatically to human dosing or clinical outcomes.

Human Clinical Trials

RegeneRx's Phase II trial of full-length thymosin beta-4 (RGN-352) in ST-elevation myocardial infarction enrolled 73 patients. The trial found no statistically significant difference in infarct size at 90 days compared with placebo (P<0.05 threshold was not met). A separate Phase II trial of thymosin beta-4 eye drops (RGN-259) for neurotrophic keratopathy showed positive signals and led to Phase III work. None of these trials tested the short TB-500 peptide specifically. Published human evidence specific to the synthetic TB-500 fragment as an injectable remains absent from peer-reviewed literature as of early 2025.

WADA Prohibition

WADA's 2024 Prohibited List places thymosin beta-4 under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). The WADA Code states:

"A substance or method shall be considered for inclusion on the Prohibited List if it meets two of three criteria: it has the potential to enhance sport performance, it represents an actual or potential health risk, or it violates the spirit of sport."

The inclusion of TB4 on the prohibited list does not constitute clinical evidence of efficacy, but it does confirm that governing bodies believe the biological activity is real enough to restrict. The full 2024 list is available at WADA's website, though that domain is outside our citation allow-list. For the underlying science WADA references, see the NIH resource on thymosin beta-4 at NIH.gov.

Risks of Unregulated TB-500 Use

Patients who obtain TB-500 from online research-chemical vendors take several specific, identifiable risks.

Purity and Contamination

Research-chemical peptides are not manufactured under FDA current Good Manufacturing Practice (cGMP) standards. A 2018 analysis of peptides sold online for "research use" found that roughly 25% of samples contained less than 90% of the labeled active ingredient, and several contained bacterial endotoxin levels exceeding United States Pharmacopeia (USP) limits for injectable preparations. Endotoxin contamination in an injectable can cause fever, systemic inflammatory response, and sepsis. The USP injectable endotoxin limit is 0.5 EU/mL for most parenteral drugs (USP Chapter 85, referenced via NIH/NCBI).

No Medical Oversight

Self-injection without a physician's involvement means no baseline labs, no monitoring for adverse effects, no drug-interaction screening, and no dose titration informed by clinical response. For someone with an autoimmune condition, cancer history, or cardiovascular disease, unmonitored use of a peptide with angiogenic and immune-modulating activity could pose specific harm.

Legal Exposure for Vendors

Purchasing from vendors who ship mislabeled drugs does not expose the individual buyer to criminal liability in most scenarios. The vendor carries the greater legal exposure. Receiving a package of injectable peptides labeled "research use only" through the mail does not guarantee trouble-free delivery. Customs can seize packages, and while individual prosecution is rare, the overall transaction remains legally murky.

What a Lawful Access Pathway Could Look Like

Given the current regulatory environment, a genuinely lawful pathway for a Louisiana patient to receive TB-500 would require several conditions to align simultaneously.

Condition 1: FDA Rulemaking Changes TB-500's Category

If the FDA moves TB-500 from Category 2 to Category 1 (the positive list) following further clinical evaluation, 503A pharmacies would be permitted to compound it. Patients with a valid prescription could then receive it from a licensed Louisiana pharmacy or a licensed out-of-state compounding pharmacy shipping to Louisiana with appropriate permits.

Condition 2: FDA-Authorized Clinical Trial

A patient could receive TB-500 legally under an Investigational New Drug (IND) application if they enrolled in an IRB-approved clinical trial. No such trials specific to the short TB-500 peptide are currently registered on ClinicalTrials.gov as of January 2025 for human subjects.

Condition 3: Individual IND (Compassionate Use)

Under 21 CFR Part 312, a physician can apply for an Individual IND (sometimes called compassionate use or expanded access) for a specific patient. This pathway exists but is rarely used for peptides without significant prior human safety data. The application process is described at FDA.gov.

Questions to Ask Any Clinic Offering TB-500 in Louisiana

Before agreeing to any TB-500 protocol through a telehealth or in-person clinic in Louisiana, patients should ask directly:

• Which specific compounding pharmacy will fill this prescription?
• Is that pharmacy registered as a 503A pharmacy with the FDA?
• How does the pharmacy document compliance with FDA bulk-substance requirements for TB-500 specifically?
• What is the Certificate of Analysis (CoA) for the batch, and can I review it before injection?
• What monitoring labs do you order at baseline and at follow-up?
• What adverse events have you observed in your patient population?

A clinic that cannot answer these questions clearly is not one a patient should trust with an injectable protocol.